Novo Nordisk Slashes Weight-Loss Drug Wegovy Prices in India

Novo Nordisk takes a bold step by cutting Wegovy’s price by up to 37% to make advanced weight-loss treatment more accessible to millions across India.

In a move that could reshape India’s fast-growing obesity treatment market, Danish pharmaceutical giant Novo Nordisk has reduced the price of its popular weight-loss drug, Wegovy, by up to 37%. The decision reflects the company’s push to make life-changing medication more affordable while strengthening its foothold in one of the world’s most promising healthcare markets.

With obesity emerging as a major public health challenge in India, the price reduction comes as a timely relief for patients. The cost of Wegovy’s highest dose (2.4 mg) has dropped from ₹24,389 to ₹16,400, while the lowest dose (0.25 mg) now costs ₹10,850, down from ₹16,260.

“We’ve listened closely to doctors and patients and taken this step to benefit as many people as possible,” said Vikrant Shrotriya, Managing Director of Novo Nordisk India.

The move intensifies the race between Novo Nordisk and U.S. rival Eli Lilly, whose drug Mounjaro has rapidly gained traction since its Indian debut in March. Both medications belong to a breakthrough class called GLP-1 receptor agonists, which help users feel fuller for longer, addressing both obesity and diabetes.

Analysts believe the price cut is also a strategic response to upcoming generic competition, as Wegovy’s patent in India expires in March 2026. With this move, Novo Nordisk is raising hope for millions seeking healthier lives.